Eisai Joins Access Accelerated To Tackle Non-Communicable Diseases

Eisai will participate in a global partnership of pharmaceutical companies to help accelerate access to health care in low and middle-income countries.

AsianScientist (Jan. 26, 2017) – Eisai Co., Ltd. has joined Access Accelerated, a global partnership to advance access to non-communicable diseases (NCDs) prevention, treatment and care in low and lower-middle income countries.

Access Accelerated is the first multi-stakeholder, international initiative in the field of NCDs, consisting of 22 major pharmaceutical companies, including Eisai, in collaboration with the World Bank Group and the Union for International Cancer Control (UICC).

The aim of Access Accelerated is to work towards the United Nation’s Sustainable Development Goal target of reducing the number of premature deaths from NCDs in low and lower-middle income countries by one-third by 2030.

In addition to the individual programs to improve access to health care run by each of the participating companies, this initiative will conduct pilots for improving prevention, treatment and care of NCDs in collaboration with the World Bank Group. Furthermore, in collaboration with the UICC, Access Accelerated will support the provision of effective, sustainable diagnosis and treatment, for the purpose of improving cancer treatment and care.

To address the global issue of NCDs, Eisai has been running various initiatives to improve access, including an Alzheimer’s disease awareness and early detection campaign in China, and the introduction of tiered pricing, an affordable pricing model for our global product anticancer agent Halaven® in seven Asian countries, including India, Thailand and the Philippines, where prices are set at several levels in accordance with the income levels of patients.

“One of the missions of the modern pharmaceutical industry is to make drugs accessible to all patients, no matter their socioeconomic status,” said Eisai CEO Mr. Haruo Naito “For Eisai, pursuing solutions for global access challenges is both our responsibility and a long-term investment into the future.”


———

Source: Eisai Co. Ltd.; Photo: Shutterstock.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.

Asian Scientist Magazine is an award-winning science and technology magazine that highlights R&D news stories from Asia to a global audience. The magazine is published by Singapore-headquartered Wildtype Media Group.

Related Stories from Asian Scientist